Real‐world experience of Fuzheng Yiqing granule as chemoprophylaxis against COVID‐19 infection among close contacts: A prospective cohort study

Author:

Che Qianzi1ORCID,Huo Ruili2,Zhao Chen1,Yang Wei1,Xiang Xinghua1,Tang Shihuan3,Shi Jiaheng4,Lu Cheng1,Li Hongmei3,Huang Luqi2

Affiliation:

1. Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences Beijing China

2. China Academy of Chinese Medical Sciences Beijing China

3. Institute of Chinese Materia Medica China Academy of Chinese Medical Sciences Beijing China

4. Guang'anmen Hospital China Academy of Chinese Medical Sciences Beijing China

Abstract

AbstractBackgroundThe objective of the current study was to evaluate whether the use of traditional Chinese medicine, Fuzheng Yiqing granule (FZYQG), was associated with a reduced infection risk of COVID‐19 in close contacts.Research design and methodsThis was a prospective cohort study across 203 quarantine centres for close contacts and secondary contacts of COVID‐19 patients in Yangzhou city. FZYQG group was defined as quarantined individuals who voluntarily took FZYQG; control group did not take FZYQG. The primary outcome was the coronavirus test positive rate during quarantine period. Logistic regression with propensity score inverse probability weighting was used for adjusted analysis to evaluate independent association between FZYQG and test positive rate.ResultsFrom July 13, 2021 to September 30, 2021, 3438 quarantined individuals took FZYQG and 2248 refused to take the granule. Test positive rate was significantly lower among quarantined individuals who took FZYQG (0.29% vs. 1.73%, risk ratio 0.17, 95% confidence interval (CI): 0.08–0.34, p < 0.001). On logistic regression, odds for test positive were decreased in FZYQG group (odds ratio: 0.16, 95% CI: 0.08–0.32, p < 0.001).ConclusionsClose and secondary contacts of COVID‐19 patients who received FZYQG had a lower test positive rate than control individuals in real‐world experience.Trial registrationThis study has been registered on Chinese Clinical Trial Registry (ChiCTR2100049590) on August 5, 2021.

Publisher

Wiley

Reference31 articles.

1. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

2. Yangzhou COVID‐19 Prevention and Control Headquarters.Notice on the quarantine period of close contacts and secondary contacts of COVID‐19 cases [EB/OL]. (2021‐08‐23) [2023‐03‐19].http://www.yangzhou.gov.cn/yzfy/zhbwj/202108/b8eecf161e1e4a72b13891e705718657.shtml

3. Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study

4. Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations

5. What do we know about covid vaccines and preventing transmission?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3